Preannouncement EP PerMed - CGT4PM2027 - Cell and Gene Therapy for Personalised Medicine

In this JTC2027, EP PerMed will fund research projects in human health on Cell and Gene Therapy (CGT) for personalised medicine approaches. Proposals must focus on the development and validation of an innovative and novel CGT for PM.

At least one of the following approaches must be employed:

• Somatic cell therapeutics; 
• Gene therapeutics ;
• Combined cell- and gene therapeutics ;
• Novel biological products such as mRNA, other nucleic acid-based methods, and extracellular vesicles as vehicle for gene-based therapeutic procedure.

Research projects in all disease areas are encouraged.

The EP PerMed overall aims to:

• Encourage and enable interdisciplinary collaborations, i.e. multi-actor research, by engaging a range of relevant disciplines such as pre-clinical and clinical research, bioinformatics/health informatics/data research, ELSA research, implementation research or health economics research connected to the proposed research topic, including end-user perspective analysis to facilitate the implementation of PM;
• Encourage cross-sectorial collaborations, by including the private sector (e.g. SMEs, small and medium-sized enterprises, industry), as well as regulatory/HTA (health technology assessment) agencies and patient organisations.

More information about the eligibility criteria and rules regarding consortium composition will be available soon.